Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • News Feature
  • Published:

The PROTAC gold rush

Nature Biotechnology volume 40, pages 12–16 (2022)Cite this article

Investment in small-molecule protein degraders is surging, but their drawbacks, limitations and risks are becoming clear.

This is a preview of subscription content, access via your institution

Relevant articles

Open Access articles citing this article.

Access options

Buy this article

  • Purchase on SpringerLink
  • Instant access to the full article PDF.

USD 39.95

Prices may be subject to local taxes which are calculated during checkout

Fig. 1: Schematic of proteolysis-targeting chimera (PROTAC) degraders.

Author information

Authors and Affiliations

  1. Ann Arbor, Michigan, USA

    Ken Garber

Authors
  1. Ken Garber
    View author publications

    Search author on:PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Garber, K. The PROTAC gold rush. Nat Biotechnol 40, 12–16 (2022). https://doi.org/10.1038/s41587-021-01173-2

Download citation

  • Published:

  • Version of record:

  • Issue date:

  • DOI: https://doi.org/10.1038/s41587-021-01173-2

This article is cited by

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing